Industry News
Pharmaceutical Industry News
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patients
In response to the Request for Input on Modernizing the 340B Drug Pricing Program issued by Representative Greg Walden and Senator Lamar Alexander, PhRMA has outlined a number of commonsense ways policymakers can get the
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others,
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
As the United States biopharmaceutical industry works around the clock to develop vaccines and treatments for COVID-19, it’s more important than ever that international trade policies facilitate patient access to innovative medicines. The pandemic has